IL-2-mediated upregulation of uPA and uPAR in natural killer cells

Biochemical and Biophysical Research Communications

Volumn 292, Issue 1, 2002, Pages 184-189

  Al Atrash, Gheath ^a   Xue, Yaming ^a   Kitson, Richard P ^a   Goldfarb, Ronald H ^a   Shetty, Sreerama ^b   Idell, Steven ^b   Halady, Prathap Kumar Shetty ^b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Cytokines; Gene regulation; Interleukin 2; NK cells; Urokinase

Indexed keywords

INTERLEUKIN 2; MESSENGER RNA; RNA; RNA BINDING PROTEIN; UROKINASE; UROKINASE RECEPTOR;

ANALYTIC METHOD; ARTICLE; CELL INVASION; CELL STIMULATION; CONTROLLED STUDY; GENE INDUCTION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR UPREGULATION; RNA ANALYSIS; RNA BINDING; RNA STABILITY; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 0036285804     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2002.6627     Document Type: Article

References (42)

1. The cell biology of leukocyte-mediated proteolysis
2. Extracellular matrix moieties, cytokines, and enzymes: Dynamic effects on immune cell behavior and inflammation
3. The plasminogen activator/plasmin system
4. The matrix metalloproteinases and their inhibitors
5. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of α 1-antitrypsin
6. Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase
7. Human cathepsin G. Catalytic and immunological properties
8. The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis
9. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression
10. The urokinase receptor is a major vitronectin-binding protein on endothelial cells
11. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin
12. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components
13. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes
14. Regulation of integrin function by the urokinase receptor
15. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion
16. Matrix metalloproteinases of human NK cells
17. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases
18. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer
19. Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration
20. Generation and characterization of purified adherent lymphokine-activated killer cells in mice
21. The expression of IL-2R alpha-chain is enhanced by activation of adenylate cyclase in large granular lymphocytes and natural killer cells
22. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells)
23. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells
24. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors
25. Matrix metalloproteinases produced by rat IL-2 activated natural killer cells
26. Natural killer cell-target cell interactions
27. Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2
28. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells
29. Interleukin 2 enhances natural killer cell activity through induction of gamma interferon
30. Ultrastructural analysis of human natural killer cell activation
31. Post-transcriptional regulation of urokinase mRNA. Identification of a novel urokinase mRNA-binding protein in human lung epithelial cells in vitro
32. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells
33. A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells
34. Posttranscriptional regulation of urokinase receptor mRNA: Identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells
35. 2B4 stimulation of YT cells induces natural killer cell cytolytic function and invasiveness
36. Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis
37. Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia
38. Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: Implications for the mechanism behind anti-tumor responses
39. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer
40. Natural killer cells: Endothelial interactions, migration, and target cell recognition
41. Evidence that induction and regulation of lymphokine-activated killer (LAK) activity are mediated by changes in tumour-binding potential of lymphocytes after activation by interleukin-2 (IL-2)
42. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets